Products & Pipeline
We are developing and commercializing novel Digital Therapeutics for a variety of indications including smoking cessation, major depressive disorder, schizophrenia, insomnia, acute coronary syndrome, migraine, overactive bladder, chronic low back pain, and obesity.
CT-100: Click Neurobehavioral Intervention (CNI) Platform
Product
Indication
Collaborator
Phase 1
Discovery
Discovery
Phase 2
Dev/Pilot
Dev/Pilot
Phase 3
Pivotal
Pivotal
Regulatory
Launch
Phase
CT-101
Clickotine®
Clickotine®
Smoking Cessation
Launch
CT-152
Rejoyn™
Rejoyn™
Major Depressive Disorder (MDD)
Otsuka
Launch
CT-132
Migraine
Regulatory
CT-155
Schizophrenia
Boehringer Ingelheim
Pivotal
CT-156
Schizophrenia
Boehringer Ingelheim
Dev/Pilot
CT-102
Opioid Use Disorder (OUD)
Indivior
Dev/Pilot
CT-133
Multiple Sclerosis (MS)
Discovery
CT-171
Atopic Dermatitis
Discovery
CT-181
Obesity
Discovery
CT-191
Oncology
Discovery
CT-141
Clickadian™
Clickadian™
Insomnia
Discovery
CT-111
Clickheart™
Clickheart™
Acute Coronary Syndrome
Discovery
Clickotine®
CT-101
An all in one, comprehensive digital smoking cessation program
learn more
Schizophrenia
CT-155
Confidential
Schizophrenia
CT-156
Confidential
Clickadian™
CT-141
Clickadian is under development as a clinically-validated fully digital program for insomnia
learn more
Clickheart™
CT-111
Clickheart is under development as a clinically-validated digital program for acute coronary syndrome
learn more
Additional Products in Research & Development
CT-131
Chronic Lower
Back Pain
Back Pain
CT-161
Overactive
Bladder
Bladder
CT-171
Atopic
Dermatitis
Dermatitis
CT-181
Obesity
CT-191
Oncology
-
Chronic Kidney
Disease
Disease
-
Chronic Obstructive
Pulmonary Disease
Pulmonary Disease
-
Osteoarthritis
Products in development are investigational Digital Therapeutics not for sale. FDA has not yet evaluated the safety or effectiveness of these products.